Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

SABR波动模型 医学 前列腺癌 随机对照试验 雄激素剥夺疗法 前列腺 放射治疗 前列腺特异性抗原 肿瘤科 内科学 放射外科 癌症 外科 经济 金融经济学 波动性(金融) 随机波动
作者
Ryan Phillips,William T. Shi,Matthew Pierre Deek,Noura Radwan,Su Jin Lim,Emmanuel S. Antonarakis,Steven P. Rowe,Ashley Evan Ross,Michael A. Gorin,Curtiland Deville,Stephen C. Greco,Hailun Wang,Samuel Ray Denmeade,Channing Judith Paller,Shirl Dipasquale,Theodore L. DeWeese,Daniel Y. Song,Hao Wang,Michael Anthony Carducci,Kenneth J. Pienta
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (5): 650-650 被引量:1263
标识
DOI:10.1001/jamaoncol.2020.0147
摘要

Importance: Complete metastatic ablation of oligometastatic prostate cancer may provide an alternative to early initiation of androgen deprivation therapy (ADT). Objective: To determine if stereotactic ablative radiotherapy (SABR) improves oncologic outcomes in men with oligometastatic prostate cancer. Design, Setting, and Participants: The Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE) phase 2 randomized study accrued participants from 3 US radiation treatment facilities affiliated with a university hospital from May 2016 to March 2018 with a data cutoff date of May 20, 2019, for analysis. Of 80 men screened, 54 men with recurrent hormone-sensitive prostate cancer and 1 to 3 metastases detectable by conventional imaging who had not received ADT within 6 months of enrollment or 3 or more years total were randomized. Interventions: Patients were randomized in a 2:1 ratio to receive SABR or observation. Main Outcomes and Measures: The primary outcome was progression at 6 months by prostate-specific antigen level increase, progression detected by conventional imaging, symptomatic progression, ADT initiation for any reason, or death. Predefined secondary outcomes were toxic effects of SABR, local control at 6 months with SABR, progression-free survival, Brief Pain Inventory (Short Form)-measured quality of life, and concordance between conventional imaging and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography in the identification of metastatic disease. Results: In the 54 men randomized, the median (range) age was 68 (61-70) years for patients allocated to SABR and 68 (64-76) years for those allocated to observation. Progression at 6 months occurred in 7 of 36 patients (19%) receiving SABR and 11 of 18 patients (61%) undergoing observation (P = .005). Treatment with SABR improved median progression-free survival (not reached vs 5.8 months; hazard ratio, 0.30; 95% CI, 0.11-0.81; P = .002). Total consolidation of PSMA radiotracer-avid disease decreased the risk of new lesions at 6 months (16% vs 63%; P = .006). No toxic effects of grade 3 or greater were observed. T-cell receptor sequencing identified significant increased clonotypic expansion following SABR and correlation between baseline clonality and progression with SABR only (0.082085 vs 0.026051; P = .03). Conclusions and Relevance: Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography. SABR induced a systemic immune response, and baseline immune phenotype and tumor mutation status may predict the benefit from SABR. These results underline the importance of prospective randomized investigation of the oligometastatic state with integrated imaging and biological correlates. Trial Registration: ClinicalTrials.gov Identifier: NCT02680587.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yingzi完成签到,获得积分10
1秒前
NexusExplorer的应助被Cold采纳,获得10
2秒前
ladyyoung完成签到,获得积分10
2秒前
3秒前
耶耶发布了新的文献求助10
3秒前
明亮涫发布了新的文献求助20
4秒前
四时令发布了新的文献求助30
4秒前
5秒前
6秒前
ayida完成签到,获得积分10
6秒前
粗犷的书蝶完成签到,获得积分20
6秒前
yhn发布了新的文献求助10
6秒前
6秒前
6秒前
漠尘完成签到,获得积分10
7秒前
7秒前
7秒前
8秒前
9秒前
9秒前
Qing发布了新的文献求助10
9秒前
9秒前
9秒前
Xueanliu发布了新的文献求助10
10秒前
wangQ发布了新的文献求助10
10秒前
12秒前
稳重电话发布了新的文献求助10
12秒前
14秒前
Felix发布了新的文献求助10
14秒前
14秒前
年轻烨霖发布了新的文献求助10
14秒前
天天向上发布了新的文献求助10
14秒前
zkb发布了新的文献求助30
15秒前
entscholar完成签到,获得积分10
16秒前
16秒前
17秒前
Owen的应助被强强采纳,获得10
17秒前
小蘑菇的应助被科研通管家采纳,获得10
17秒前
Owen的应助被科研通管家采纳,获得10
17秒前
所所的应助被科研通管家采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193599
求助须知:如何正确求助?哪些是违规求助? 9579723
关于积分的说明 21867157
捐赠科研通 7793198
什么是DOI,文献DOI怎么找? 3437314
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484193